Pro Research: Wall Street digs into Neurocrine Biosciences’ prospects
Post Content
Similar Posts
China wealth manager Zhongzhi flags insolvency, $64 billion in liabilities
Post Content Post Views: 138
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Before successful weight loss treatments such as Wegovy and Ozempic, the pharmaceutical path to treating obesity was strewn with failures dating back decades. Post Views: 136
India’s bond market set for growth with central bank rate cuts
Post Content Post Views: 132
Microsoft and tech peers outperform as Treasury yields fall
Post Content Post Views: 149
Ethereum holds steady, poised for potential breakout
Post Content Post Views: 153
First Quantum starts international arbitration on Cobre Panama mine
Post Content Post Views: 133